SRx Health (SRXH) Enterprise Value to EBITDA Ratio

Public company logo of SRx Health Solutions (SRXH)

SRx Health Solutions Inc. (SRXH) relies on predictable cash flows due to its service-based healthcare delivery model. This price chart on the GURU.Markets platform demonstrates an EV/EBITDA value of 0.00. The business minimizes product shortages through cold chain automation, while the implementation of a personalized client approach allows it to avoid dumping and maintain high profitability even under significant pressure from market peers.

SRx Health Solutions - SRXH Company Value to EBITDA (period 11/23/2025 - 11/15/2026)

Comprehensive metric breakdowns and analytics for SRx Health Solutions Inc (SRXH)

- current price and projected stock value:
Stock Price srxhealth.com|SRXH - Analyst Median Target
- market capitalization details:
Market Valuation SRx Health Solutions|SRXH - Full Business Value
- business book valuation details:
Book Value per Share SRx Health Solutions|SRXH - Total Stockholders' Equity|Market Capitalization to Book Value Ratio srxhealth.com|SRXH - Total Business Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio SRx Health Solutions Inc.|SRXH - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity SRx Health Solutions Inc|SRXH - Company Aggregate Indebtedness|Debts to Book Capitalization SRx Health Solutions Inc|SRXH - Company Long-Term Loans and Borrowings|Company Short-Term Debts SRx Health Solutions|Quick Liquidity srxhealth.com
- financial results and valuation multiples details:
SRXH - Final Profit|Expected Profit SRx Health Solutions Inc.|SRXH - Price to Earnings Ratio|Forward P/E Multiple SRx Health Solutions Inc|SRXH - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SRx Health|SRXH - Operating income before deduction of amortization|Earnings per share for the last twelve months SRx Health Solutions|SRXH - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months srxhealth.com|SRXH - Earnings per share growth this year|Expected earnings per share growth for next year SRx Health Solutions Inc.
- revenue and sales details:
SRXH - Company Sales Revenue|Projected Sales Volume SRx Health Solutions Inc.|SRXH - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple SRXH
Fundamental valuation:SRx Health Solutions SRXH
Manufactured products of SRx Health Solutions

SRx Health Solutions Inc. (SRXH) investments in pharmacy chain robotization require significant capital, making the Enterprise Value to EBITDA multiple a key tool for comparing the total business value with its operating profit before interest and taxes. The current sideways movement of this metric confirms a fair balance between debt load and cash flow generation, signaling the stability of the company's market valuation.

Key competitors

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma Inc (BBIO)|Enterprise Value to EBITDA Ratio BGM|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Biosciences, Inc.)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma Holdings)|KROS (Keros Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharma) - Company Value to Operating Income Before Depreciation Ratio|Kamada Ltd. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Therapeutics)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group PLC (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics Inc. (APLT)|Enterprise Value to EBITDA Ratio Rein Therapeutics Inc RNTX|EV/EBITDA Multiple GELS (Gelteq Ltd)|EV/EBITDA Multiple Aytu Therapeutics AYTU|Chemomab Therapeutics Ltd. - EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI